Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 10/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 5/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113423 | 0.94 | HTR4 (0.59) | HTR4CYP3A4ACHEDCPSCNR2 | |
| SCHEMBL5116821 | 0.93 | HTR4 (0.57) | HTR4CYP3A4ACHEHCRTR2 | |
| SCHEMBL5119519 | 0.93 | HTR4 (0.60) | HTR4CYP3A4ACHEDCPSCNR2 | |
| SCHEMBL21081780 | 0.92 | HTR4 (0.63) | HTR4CYP3A4ACHEDCPSCNR2 | |
| SCHEMBL5114319 | 0.92 | HTR4 (0.66) | HTR4CYP3A4ACHEDCPSCNR2 | |
| SCHEMBL21081785 | 0.91 | HTR4 (0.62) | HTR4CYP3A4ACHEDCPSCNR2 | |
| Hydrochloric Acid SCHEMBL17275530 | 0.91 | HTR4 (0.65) | HTR4CYP3A4ACHEDCPSHCRTR2 | |
| SCHEMBL17275529 | 0.91 | HTR4 (0.65) | HTR4CYP3A4ACHEDCPSCNR2 | |
| Bromide SCHEMBL17275534 | 0.91 | HTR4 (0.65) | HTR4CYP3A4ACHEDCPSCNR2 | |
| Potassium Ion SCHEMBL17275541 | 0.91 | HTR4 (0.65) | HTR4CYP3A4ACHEDCPSCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108658964-B | Polymorphic substance | 拉夸里亚创药株式会社 | 2021-07-02 | — | — | CN | disclosed |
| US-10179779-B2 | Polymorph forms | RAQUALIA PHARMA INC. (JP) | 2019-01-15 | — | — | US | disclosed |
| EP-2710002-B1 | POLYMORPH FORM OF 4-{[4-({[4-(2,2,2-TRIFLUOROETHOXY)-1,2-BENZISOXAZOL-3-YL]OXY}METHYL)PIPERIDIN-1-YL]METHYL}-TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID | RAQUALIA PHARMA INC (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-9187463-B2 | Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid | RAQUALIA PHARMA INC. (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150322055-A1 | POLYMORPH FORMS | RAQUALIA PHARMA INC. (JP) | 2015-11-12 | — | — | US | disclosed |
| EP-2922849-A1 | POLYMORPH FORMS | RaQualia Pharma Inc (JP) | 2015-09-30 | — | — | EP | disclosed |
| US-8816090-B2 | Benzisoxazole derivatives | PFIZER INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-1856114-B1 | BENZISOXAZOLE DERIVATIVES | PFIZER (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20140187583-A1 | Polymorph Form of 4-methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid | RAQUALIA PHARMA INC. (JP) | 2014-07-03 | — | — | US | disclosed |
| WO-2014080633-A1 | POLYMORPH FORMS | RAQUALIA PHARMA INC. (JP) | 2014-05-30 | — | — | WO | disclosed |
| EP-2710002-A1 | POLYMORPH FORM OF 4-{[4-({[4-(2,2,2-TRIFLUOROETHOXY)-1,2-BENZISOXAZOL-3-YL]OXY}METHYL)PIPERIDIN-1-YL]METHYL}-TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID | RaQualia Pharma Inc (JP) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012157288-A1 | POLYMORPH FORM OF 4-{[4-({[4-(2,2,2-TRIFLUOROETHOXY)-1,2-BENZISOXAZOL-3-YL]OXY}METHYL)PIPERIDIN-1-YL]METHYL}-TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID | RAQUALIA PHARMA INC. (JP) | 2012-11-22 | — | — | WO | disclosed |
| US-20080207690-A1 | Benzisoxazole Derivatives | RAQUALIA PHARMA INC. (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1856114-A1 | BENZISOXAZOLE DERIVATIVES | Pfizer, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006090224-A1 | BENZISOXAZOLE DERIVATIVES | PFIZER JAPAN INC. (JP) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207690-A1 | Benzisoxazole Derivatives | BRS3, MRGPRX4, HTR4 | HTR4 3/4885CYP3A4 142/4885ACHE 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.